Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trials

P.B Duell,M Banach,A.L Catapano,U Laufs,G.B.J Mancini,K.K Ray,L.T Bloedon,Z Ye,A.C Goldberg

doi:10.1016/j.atherosclerosis.2020.10.050

Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trials

P.B Duell, M Banach + Show 7 more

https://doi.org/10.1016/j.atherosclerosis.2020.10.050

Copy DOI

Journal: Atherosclerosis	Publication Date: Dec 1, 2020
Citations: 7

Affiliation: Oregon Health & Science University, Medical University of Lodz, University of Milan, University Hospital Leipzig, Klinik und Poliklinik für Neurologie, University of British Columbia, Imperial College London, Esperion Therapeutics (United States), University of Washington

#Safety Of Bempedoic Acid #Heterozygous Familial Hypercholesterolemia + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Background and Aims: Patients with heterozygous familial hypercholesterolemia (HeFH) have high cardiovascular risk due to lifelong elevated levels of low-density lipoprotein cholesterol (LDL-C), often requiring multidrug therapy to achieve sufficient LDL-C lowering. In patients with and without HeFH, we evaluated efficacy and safety of bempedoic acid (BA), an investigational, oral, once-daily, ATP-citrate lyase inhibitor, when added to existing lipid-lowering therapy (LLT).

Full Text